Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q2 2023 · 10-Q
Revenue$183.50M$183.50M+2.3% vs Q2 2022 Net Income-$116.10M-$116.10MN/M vs Q2 2022 EPS Diluted-$1.42-$1.42N/M vs Q2 2022 Operating Income-$113,700,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$19,700,000N/M Margins · derivedOperating margin-62.0%−52.0 pt vs Q2 2022
Net margin-63.3%−55.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 4, 2023 · 35 d after period end